Moderna's revenue from its COVID-19 vaccine is expected to drop 72.8 percent, from $18.4 billion to a minimum of $5 billion, from 2022 to 2023's annual sales, the company said Jan. 9.
Here are four other recent updates from the vaccine-maker:
1. The company has 48 programs in development, including 36 in ongoing clinical studies.
2. It projects spending $4.5 billion in 2023 on research and development.
3. On Jan. 4, the company said it would acquire genomics company OriCiro for $85 million.
4. Moderna will collaborate with an oncology business to investigate potential therapeutic options for mRNA, the technology used in its COVID-19 vaccine.